Central Histaminergic Signaling, Neural Excitability and Epilepsy
- Lin Yang,
- Yi Wang,
- Zhong Chen
Abstract
Epilepsy is a common neurological disorder characterized by repeated and
spontaneous epileptic seizures, which is not well controlled by current
medication. Traditional theory supports that epilepsy results from the
imbalance of excitatory glutamate neurons and inhibitory GABAergic
neurons. Recently, shreds of evidence from available clinical and
preclinical researches suggest that histamine in the central nervous
system plays an important role in the modulation of neural excitability
and pathogenesis of epilepsy. Many histamine receptor ligands show
positive response in animal epilepsy models, among which the H3R
antagonist pitolisant even has shown a good anti-epileptic effect in
clinical trials. New insights are focusing on the potential action of
histamine receptors to control and treat epilepsy. This review
summarizes the findings from animal and clinical researches on the role
of brain histamine and histamine receptor in epilepsy. Importantly, we
further provide perspectives on some possible research directions for
future studies.22 Dec 2020Submitted to British Journal of Pharmacology 22 Dec 2020Submission Checks Completed
22 Dec 2020Assigned to Editor
30 Dec 2020Reviewer(s) Assigned
09 Feb 2021Review(s) Completed, Editorial Evaluation Pending
10 Feb 2021Editorial Decision: Revise Minor
02 Mar 20211st Revision Received
02 Mar 2021Submission Checks Completed
02 Mar 2021Assigned to Editor
02 Mar 2021Reviewer(s) Assigned
23 Jul 2021Review(s) Completed, Editorial Evaluation Pending
23 Jul 2021Editorial Decision: Revise Minor
18 Aug 20212nd Revision Received
19 Aug 2021Submission Checks Completed
19 Aug 2021Assigned to Editor
24 Aug 2021Reviewer(s) Assigned
31 Aug 2021Review(s) Completed, Editorial Evaluation Pending
03 Sep 2021Editorial Decision: Revise Minor
06 Sep 20213rd Revision Received
07 Sep 2021Submission Checks Completed
07 Sep 2021Assigned to Editor
08 Sep 2021Review(s) Completed, Editorial Evaluation Pending
12 Sep 2021Editorial Decision: Accept